ChronoScale Corp

Listed Company

CHRNCIK 0001549084NasdaqNon-AcceleratedSmaller ReportingGeneral Industrial Machinery & Equipment, NecNevadaFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-11.70M

Total Assets

—

Equity

—

Shares Out

3.56M

Op. Cash Flow

$-11.80M

Business

EKSO BIONICS HOLDINGS, INC. designs, develops, and markets wearable robotic exoskeletons that augment human strength, endurance and mobility for healthcare and industrial applications. Main products include EksoNR, Ekso Indego Therapy, Ekso Indego Personal, Nomad and Ekso EVO, together with services such as EksoCare, device servicing and clinical and online training. The company operates one reportable operating segment with two markets—Enterprise Health and Personal Health—generating revenue from device sales, subscriptions and support contracts. It distributes products globally through direct and distributor channels across the Americas, EMEA and APAC to hospitals, rehabilitation centers, industrial customers, DMEs and individual users.

Summary from filing dated 2025-03-03

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	13	18	18	13	11
Cost of revenue	6	8	9	7	4
Gross profit	7	10	9	6	7
Sales and marketing	7	7	8	7	7
Research and development	3	4	5	4	3
General and Administrative Expense	10	9	11	11	11
Total operating expenses	20	20	24	22	21
Loss from operations	−13	−10	−15	−16	−14
Interest expense, net	−309,000	−269,000	−302,000	—	—
Gain on revaluation of warrant liabilities	1,000	474,000	−133,000	1	—
Loss on modification of warrant	0	−109,000	0	0	1
Unrealized gain (loss) on foreign exchange	2	−965,000	412,000	−655,000	−867,000
Other expense, net	−26,000	−1,000	−63,000	−30,000	−17,000
Total other income (expense), net	2	−870,000	−86,000	476,000	4
Net loss	−12	−11	−15	−15	−10
Foreign currency translation adjustments	−2	801,000	−407,000	580,000	830,000
Comprehensive loss	−13	−11	−16	−15	−9
Net loss per share applicable to common shareholders, basic and diluted (in dollars per share)	−4.91	−8.43	−1.1	−1.16	−0.8
Weighted average number of shares outstanding, basic and diluted (in shares)	2	1	14	13	12

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash	1	4	9	21	40
Restricted cash	0	2	—	—	—
Accounts receivable, net of allowances of $27 and $33, respectively	7	7	6	5	5
Inventories	5	5	5	5	2
Prepaid expenses and other current assets	750,000	541,000	875,000	700,000	485,000
Total current assets	14	19	20	31	48
Property and equipment, net	1	2	2	3	991,000
Right-of-use assets	532,000	788,000	977,000	1	216,000
Intangible assets, net	4	5	5	5	0
Goodwill	431,000	431,000	431,000	431,000	0
Other assets	311,000	433,000	392,000	231,000	164,000
Total assets	20	27	29	41	49
Accounts payable	1	2	2	3	3
Accrued liabilities	2	2	3	2	2
Deferred revenues, current	2	2	2	1	1
Convertible promissory note, net	2	0	—	—	—
Notes payable, current	1	1	1	2	0
Lease liabilities, current	441,000	427,000	363,000	341,000	229,000
Total current liabilities	9	8	8	9	7
Deferred revenues	1	2	2	1	1
Notes payable, net	798,000	4	5	4	2
Lease liabilities	147,000	452,000	723,000	1	0
Warrant liabilities	0	1,000	366,000	233,000	—
Other non-current liabilities	89,000	181,000	105,000	141,000	74,000
Total liabilities	11	14	16	15	12
Commitments and contingencies (Note 15)	—	—	—	—	—
Convertible preferred stock, $0.001 par value; 10,000 shares authorized; no shares issued and outstanding as of December 31, 2025 and 2024	0	0	0	0	0
Common stock, $0.001 par value; 141,429 shares authorized; 3,559 and 1,480 shares issued and outstanding as of December 31, 2025 and 2024, respectively	37,000	22,000	15,000	13,000	13,000
Additional paid-in capital	272	262	252	249	246
Accumulated other comprehensive (loss) income	−692,000	957,000	156,000	563,000	−17,000
Accumulated deficit	−262	−250	−239	−224	−209
Total stockholders' equity	9	13	13	25	37
Total liabilities and stockholders' equity	20	27	29	41	49

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	2	2	2	887,000	1
Loss on impairment of intangible assets	750,000	0	—	—	—
Changes in provision for credit losses on accounts receivable	−50,000	171,000	72,000	33,000	75,000
Common stock contribution to 401(k) plan	151,000	257,000	378,000	186,000	171,000
Stock-based compensation expense	1	1	2	3	2
Accounts receivable	446,000	−2	−1	−67,000	−2
Inventories	−275,000	257,000	232,000	−1	−752,000
Prepaid expenses and other assets current and noncurrent	−187,000	329,000	−158,000	−303,000	19,000
Accounts payable	−137,000	−288,000	−1	−102,000	2
Accrued, lease and other current and noncurrent liabilities	−1	−599,000	−134,000	−197,000	379,000
Deferred revenues	−783,000	−257,000	2	−511,000	−564,000
Net cash used in operating activities	−12	−10	−12	−15	−11
Acquisition of property and equipment	−188,000	−37,000	−157,000	−194,000	−59,000
Net cash used in investing activities	−188,000	−37,000	−157,000	−5	−59,000
Principal payments under note payable	−1	−1	−313,000	0	0
Proceeds from issuance of common stock, net	4	9	661,000	0	37
Proceeds from exercise of warrants, net	4	0	—	0	1
Net cash provided by financing activities	7	8	348,000	0	39
Net decrease in cash	−5	−2	−12	−20	28
Effect of exchange rate changes on cash	36,000	−31,000	−24,000	−18,000	47,000
Cash paid for interest	118,000	182,000	191,000	126,000	1,000
Cash paid for income taxes	5,000	8,000	45,000	13,000	104,000
Deemed dividend in connection with warrant inducement	226,000	0	—	—	—
Share issuance for common stock contribution to 401(k) plan	236,000	238,000	250,000	176,000	152,000
Transfer of inventory to property and equipment	77,000	199,000	−82,000	385,000	434,000
Initial recognition of operating lease liabilities and right of use assets	153,000	180,000	−10,000	1	0

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro